Oramed CFO granted 95,889 RSUs in Form 4

Oramed Pharmaceuticals Chief Financial Officer Avraham Gabay received an equity grant of 95,889 Restricted Stock Units (RSUs).

Rhea-AI Filing Summary

Oramed Pharmaceuticals Chief Financial Officer Avraham Gabay received an equity grant of 95,889 Restricted Stock Units (RSUs). The RSUs vest in eight equal quarterly installments beginning on April 1, 2026, encouraging longer-term retention. Each RSU converts into one share of common stock when it vests, bringing his direct holdings to 745,145 shares after the award.

Insider Trade Summary

Grant/Award: 95,889 shares

Grant/Award 1 txn

Insider Gabay Avraham

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	95,889	$0.00	$0.00

Holdings After Transaction: Common Stock — 745,145 shares (Direct)

Footnotes (1)

1. F1. Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Oramed (ORMP) CFO Avraham Gabay report in this Form 4?

Oramed CFO Avraham Gabay reported receiving 95,889 Restricted Stock Units as an equity award. These RSUs are compensation-related and not an open-market purchase or sale, so they reflect routine executive compensation rather than a discretionary trading decision.

How many Oramed (ORMP) RSUs were granted to the CFO and what do they represent?

The CFO received 95,889 Restricted Stock Units, each representing the right to obtain one share of Oramed common stock. When RSUs vest, they convert into actual shares, aligning executive compensation with future company performance and stock price over time.

What is the vesting schedule for the Oramed (ORMP) CFO’s 95,889 RSUs?

The 95,889 RSUs granted to Oramed’s CFO will vest ratably in eight quarterly installments starting April 1, 2026. This means a portion of the award becomes shares every quarter, encouraging ongoing service and long-term alignment with shareholder interests.

How many Oramed (ORMP) shares does the CFO hold after this RSU grant?

Following the RSU award, the CFO’s direct holdings are reported as 745,145 shares of Oramed common stock. This total includes the impact of the new RSU grant as reported in the filing, providing context for the scale of his equity position.

Is the Oramed (ORMP) CFO’s RSU award an open-market buy or sell transaction?

No, the RSU award is classified as a grant or award acquisition, not an open-market buy or sell. It is part of the executive compensation structure, meaning the CFO did not pay cash to acquire these units and did not sell shares in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 05:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gabay Avraham

(Last) (First) (Middle)

1185 AVENUE OF THE AMERICAS

THIRD FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		A		95,889(1)	A	$0(1)	745,145	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer.

	/s/ Avraham Gabay	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)